Novavax Earnings Call Transcripts
Fiscal Year 2026
-
The company has pivoted to a partnership-driven model, leveraging its Matrix-M technology to secure major deals with Sanofi and Pfizer, and is advancing a robust R&D pipeline targeting vaccines and immunotherapies. Financial discipline and strong IP position support a path to profitability by 2028.
-
The company has pivoted to a platform and partnership-driven strategy, highlighted by major deals with Sanofi and Pfizer, expansion of its Matrix-M adjuvant platform, and a robust early-stage pipeline. Financially, it targets profitability by 2028, supported by a strong cash runway and cost reductions.
-
The company has transformed from a single-asset focus to a diversified platform strategy, achieving major cost reductions and expanding partnerships with leading pharma companies. Key catalysts for 2026 include Sanofi’s full U.S. launch, new partnership opportunities, and advancing early-stage pipeline assets.
Fiscal Year 2025
-
Revenue grew 65% year-over-year to $1.1B in 2025, driven by partnerships and cost reductions. Cash runway extends into 2028, with 2026 revenue guidance of $230–$270M and further expense cuts planned. Matrix-M technology and new deals with Pfizer and Sanofi underpin future growth.
-
A strategic shift is underway, focusing on partnerships, notably with Sanofi, to commercialize vaccines and leverage the Matrix-M adjuvant platform. The pipeline targets high unmet needs in infectious disease and oncology, with AI-driven innovation and multiple pharma collaborations.
-
Q3 2025 saw continued transformation with a shift to a partnership and R&D-driven model, highlighted by expanded Sanofi collaboration, cost reductions, and a diversified pipeline. Revenue was $70M, with a net loss of $202M, and 2025 guidance was raised. Non-GAAP profitability is now targeted for 2028.
-
The conference highlighted a strategic transformation to a lean, multi-asset biotech, with a major Sanofi partnership driving commercialization and growth. The company is leveraging its Matrix-M technology for new deals and a robust R&D pipeline, targeting profitability by 2027.
-
Q2 2025 saw strong operational progress, highlighted by a $175M Sanofi milestone, reduced expenses, and robust R&D pipeline advances. Updated 2025 revenue guidance is $1.0B–$1.05B, with non-GAAP profitability targeted by 2027, supported by growing partnerships and lean operations.
-
The company has transitioned to an R&D and partnership-driven model, highlighted by a major Sanofi deal and a focus on its Matrix-M platform. Key milestones include new vaccine launches, significant cost reductions, and a robust early-stage pipeline, with profitability targeted by 2027.
-
Leadership highlighted strategic transformation, expanded Matrix-M partnerships, and a robust pipeline. Regulatory progress continues with BLA approval expected soon, while financials improve through cost reductions and milestone-driven revenue. Major pharma collaborations and new clinical data are anticipated.
-
Q1 2025 revenue surged to $667M, driven by APA closeouts, with net income at $519M. Cost reductions and new partnerships support a raised 2025 revenue outlook of $975M–$1.25B, while progress continues on pipeline and regulatory milestones.
-
Leadership outlined a new strategy focused on R&D, innovation, and outlicensing, highlighted by a major partnership with Sanofi and expansion of Matrix-M collaborations. The pipeline targets high-value markets, and financial strength supports future growth and deal-making.
-
The company is executing a new strategy centered on R&D, partnerships, and the Matrix-M platform, with the Sanofi deal providing major financial milestones and royalties. Multiple top pharma companies are now engaged, and key 2025 catalysts include regulatory milestones, new deals, and pipeline data releases.
Fiscal Year 2024
-
2024 saw a strategic pivot to R&D and partnerships, highlighted by a major Sanofi deal, significant cost reductions, and a shift to milestone and royalty revenue. 2025 will be a transition year, with profitability targeted for 2027, contingent on Sanofi's commercial execution.
-
A major licensing deal with Sanofi is set to expand market reach for the COVID vaccine and future combos, while proprietary flu and COVID-flu programs advance toward phase III. The company is reducing costs, broadening its pipeline, and maintains over $1 billion in cash.
-
Q3 2024 revenue was $85M, with U.S. COVID-19 vaccine sales up significantly year-over-year but market share at 3%. Full-year revenue guidance was lowered, while cost reductions and the Sanofi partnership are expected to drive future value through milestones and royalties.
-
Recent U.S. COVID vaccine authorization and a transformative Sanofi partnership are driving growth, with a robust late-stage pipeline and significant cost reductions underway. Revenue guidance is $700–$800 million for 2024, and key phase 3 trials will read out mid-next year.
-
Four strategic pillars drive value: a major Sanofi partnership, late-stage pipeline progress, Matrix-M technology expansion, and disciplined cost reduction. Matrix-M’s versatility and the upcoming combination vaccine phase III data are key near-term catalysts. Commercial execution and a leaner model support a path to profitability.
-
Q2 2024 revenue reached $415M, driven by the Sanofi partnership, with significant cost reductions and a strategic shift toward R&D and partnerships. Updated COVID-19 vaccine is on track for the 2024–2025 season, and a phase 3 trial for flu/COVID combo is set for Q4.
-
Significant progress was made on strategic, financial, and product fronts, including a transformative Sanofi partnership, regulatory advances for the COVID vaccine, and a robust late-stage pipeline. Operational costs have been sharply reduced, and the company is positioned for further growth and value creation.